Ring-shaped extrachromosomal DNA is implicated in many cancers. Rachel Brazil talks to the scientists trying to uncover their ...

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor ...

Any recent news or things you're looking to announce next year? Zach Hornby: Our first clinical programme, BBI355, is an oral CHK1 inhibitor. We should read out data from our Phase 1b component by ...

Mechanistically, the compound induced cell cycle arrest: in SW-480 and Caco-2 cells, it halted progression at the S phase through the ATR/Chk1 pathway, while in HCT-116 cells, it caused arrest at ...

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial ...

I have also supervised PhD studentships on chK1 in small cell lung cancer and AURKA expression and radiosensitivity in NSCLC. I am the EORTC Co-ordinator on the international SPLENDOUR study of ...

CEP135 associates with SAS6 to link it to CPAP. Checkpoint kinase 1 (CHK1) phosphorylates and inhibits cell division cycle 25 (CDC25) A/C, which is responsible for dephosphorylating and activating ...

In addition to PARP and DNA-PK inhibitors, ATR, CHK1, and WEE1 inhibitors are under development and being tested in current clinical trials alone or in combination with chemotherapy (Brown et al., ...

School of Medicieneand Popuoation Health, University of Sheffield, Sheffield, UK. It is commonly understood that DNA damage is largely sensed and repaired in interphase and it is proposed that DNA ...